You are here

Article Text

Article menu
Download PDFPDF
Online mutation report
Mutational and gross deletion study of the MEN1 gene and correlation with clinical features in Spanish patients
  1. A Cebrián1,
  2. S Ruiz-Llorente1,
  3. A Cascón1,
  4. M Pollán2,
  5. J J Díez3,
  6. A Picó4,
  7. D Tellería1,
  8. J Benítez5,
  9. M Robledo1
  1. 1Hereditary Endocrine Cancer Group, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
  2. 2Department of Cancer Epidemiology, Centro Nacional de Epidemiología, Madrid, Spain
  3. 3Endocrinology Service, Hospital Ramón y Cajal, Madrid, Spain
  4. 4Endocrinology Service, Hospital General de Alicante, Alicante, Spain
  5. 5Human Genetics Department, Molecular Pathology Programme, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
  1. Correspondence to:
 Dr M Robledo, Hereditary Endocrine Cancer Group, Molecular Pathology Programme, Centro Nacional de Investigaciones Oncológicas, C/ Melchor Fernández Almagro 3, 28029 Madrid, Spain; 
 mrobledo{at}cnio.es

https://doi.org/10.1136/jmg.40.5.e72

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Multiple endocrine neoplasia type 1 (MEN1, OMIM 131100) is an autosomal dominant disorder characterised by the combination of endocrine tumours, such as parathyroid tumours, enteropancreatic tumours, anterior pituitary tumours, adrenal gland, and neuroendocrine carcinoid tumours, as well as non-endocrine expression, such as lipoma, facial angiofibroma, collagenoma, and ependymoma.1,2 Primary hyperparathyroidism (HPT) is the first manifestation of MEN1 in approximately 90% of patients, although this percentage differed between studies.3,4 Gastrinoma is the most frequent enteropancreatic tumour, accounting for approximately 40% of enteropancreatic tumours.2 It has thus been suggested that MEN1 syndrome should be excluded in patients with gastrinoma.5 Prolactinomas account for 20% of MEN1 related pituitary lesions,1,2 while other reported pituitary tumours are relatively uncommon manifestations of MEN1.1,2

    The MEN1 gene is located on chromosome 11q136,7 and was positionally cloned in 1997.8,9 It contains 10 exons and encodes menin, a 610 amino acid protein. Menin is known to be a nuclear protein10 that represses JunD activated transcription11 and interacts with other proteins, such as Smad3,12 nm23,13 and NF-κB,14 all of which are involved in the regulation of cell proliferation and development.

    Inactivating germline mutations found in MEN1 families/patients indicates that the MEN1 gene is a tumour suppressor gene.8,9 More than 200 germline and somatic mutations have been identified to date but no hot spots or genotype-phenotype correlations have been observed. Consequently, carriers in a family with MEN1 should be checked periodically for typical and less frequent expressions of the MEN1 syndrome. Taking into account both the absence of hot spots for mutations in the MEN1 gene and the lack of genotype-phenotype correlations, it is necessary to establish clinical criteria in order to increase the detection rate of MEN1 germline mutations. …

    View Full Text